The use of labeled fusion protein for detection of B19 parvovirus IgM antibodies by an immunocapture test.
J Virol Methods
; 32(1): 21-30, 1991 Apr.
Article
en En
| MEDLINE
| ID: mdl-1648571
ABSTRACT
A new anti-B19 IgM ELISA was developed taking advantage of antibody-capture with biotinylated fusion protein as antigen. Specificity was examined using serum IgM antibody positive for rubella, hepatitis B core antigen, cytomegalovirus and Epstein-Barr virus as well as with sera positive for rheumatoid factors or antinuclear antibodies. The specificity was found to be 96%. Of one hundred serum samples compared using the new ELISA or the standard MACRIA tests for the presence of B19 IgM, 88 gave the same results. Fifty-three were negative and 35 were positive. Six sera were ELISA-negative MACRIA-positive, and six MACRIA-negative ELISA-positive. Thus, the ELISA gave 90% agreement with MACRIA. In a clinical study with 725 sera from suspected B19 infections, 161 (22%) were found positive by ELISA. The positive sera were from patients suffering from arthritis (35%), rash (35%), acute or chronic erythroblastopenia (21%), pancytopenia (5%), vascular purpura (2%) and lymphadenopathy (2%). A series of serum specimens obtained from two-B19 infected individuals were also studied. The IgM antibody became undetectable after four months.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Parvoviridae
/
Inmunoglobulina M
/
Ensayo de Inmunoadsorción Enzimática
/
Infecciones por Parvoviridae
/
Anticuerpos Antivirales
Tipo de estudio:
Diagnostic_studies
Idioma:
En
Año:
1991
Tipo del documento:
Article